PharmExec Blog
Follow Us
RSS
Bookstore
Technology News- BioPharm News
- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
- Clinical Trials News
- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Tag Archives: Lilly
Lilly Osteoporosis Drug Canned in Phase III Trials
Image by go elsewhere… via Flickr
Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials.
The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.†[...]
Posted in Strategy Also tagged arzoxifene, Breast cancer, Clinical trial, GENERATIONS, Osteoporosis drug market, U.S. Food and Drug Administration Leave a comment
Lilly Sales Force Buyouts Revealed
Image via Wikipedia
Lilly, on Tuesday, announced that it will offer 4,000 sales reps a buyout in hopes of reducing its sales force by 300 before year’s end. According to a Lilly spokesperson, this is a voluntary exit program for eligible sales force professionals in its diabetes, neuroscience, and osteoporosis business units. Reps have the opportunity [...]
Pharm Exec Podcast Series:
Bill Trombetta Industry Audit (Part 2)
[display_podcast]
Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special.
Eli Lilly: With double-digit growth in sales, and a solid improvement in revenue per employee, Lilly placed fourth in the Company of the Year rundown. Bill Trombetta explains Lilly’s position as a big/small pharma and [...]
Lilly Puts Up $6.5 Billion for ImClone
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever.
With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer.
ImClone also [...]
Saving Haiti: One Donation at a Time (UPDATED 1/21)